AGIO: Agios Pharmaceuticals, Inc. Company Profile & Statistics

Agios Pharmaceuticals, Inc. Profile

About

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

Info & Links

CEO

Brian Goff

Headquarters

88 SIDNEY STREET
CAMBRIDGE, MA 02139, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

Employees

540

Agios Pharmaceuticals, Inc. Statistics

Valuation Measures

Market Capitalization²

1.75B

Enterprise Value

1.67B

Enterprise Value/EBITDA(ttm)

-3.51

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

30.74

Price to Book(mrq)

1.39

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

87.86%

Operating Margin(ttm)

-764.01%

Profit Margin(ttm)

-816.70%

Return on Equity(ttm)

-31.07%

Return on Invested Capital(ttm)

-31.38%

Return on Assets(ttm)

-28.92%

Income Statement

Revenue(ttm)

54.03M

Revenue Per Share(ttm)

0.92

Gross Profit(ttm)

47.68M

EBITDA(ttm)³

-474.15M

Net Income Available to Common(ttm)

-412.78M

Diluted EPS(ttm)

-7.11

Share Statistics

Beta (5Y Monthly)

0.89

52-Week Change

-2.62%

S&P 500 52-Week Change

13.39%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

58.59M

Dividend Yield

0.00%

Float⁴

56.07M

% Held by Insiders

4.30%

% Held by Institutions

Balance Sheet

Total Cash(mrq)

854.42M

Total Cash Per Share(mrq)

14.58

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

11.46%

Quick Ratio(mrq)

11.06%

Book Value Per Share(mrq)

20.41

Cash Flow

Operating Cash Flow Per Share(ytd)

-6.43

Free Cash Flow(ytd)

-377.29M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

AGIO

Agios Pharmaceuticals, Inc.